Web of knowledge for

NANOSILVA

Contract number 83/2017

National Authority: UEFISCDI

UNIVERSITATEA BABES BOLYAI

FACULTATEA DE CHIMIE SI INGINERIE CHIMICA

Innovative composites with antimicrobial properties comprising ceramic nanoparticles and silver nanoparticles, functionalized with biomolecules, embedded into polymer matrix

HOME

OBJECTIVES

EXPECTED RESULTS

OBTAINED RESULTS

DISSEMINATION

PCAS

·   National Authority: Executive Unit for Financing Higher Education,

                                    Research, Development and Innovation (UEFISCDI).

·   Contract number: 83/2017

·   Project code: PN-III-P4-ID-PCE-2016-0875

·   Project leader:  Ass. Prof. Dr. Aurora Mocanu

         (email: amocanu@chem.ubbcluj.ro)

CO – Babes-Bolyai University of Cluj-Napoca

          http://www.ubbcluj.ro

Abstract

Innovative composites with antimicrobial properties comprising ceramic nanoparticles and silver nanoparticles, functionalized with biomolecules, embedded into polymer matrix are the main products of NanoSilva projects. The NanoSilva project has a major scope to develop innovative strategies for safe production of advanced composite materials, functionalized with antimicrobial compounds (AMC), mostly antibiotics for medical applications. To achieve this aim, the antimicrobial properties of silver nanoparticles (AgNPs) will be conjugated with those of the traditional AMC to benefit from their synergistic effect. Nano hydroxyapatite (HAP) will be used as support for the AgNPs, and for AMC composites by using appropriate polymers. The necessity for such novel antimicrobial materials results from the situation created by the apparition of microbial strains with multiple drug resistances as a consequence of the extensive and sometimes abusive use of antibiotics to fight infections. The safe production of NanoSilva products will imply a green synthesis avoiding any potential toxic reagents. NanoSilva products will be characterized by physical and chemical methods, and their antibacterial efficiency will be assessed by biologic methods. The NanoSilva composites, developed and validated in laboratory conditions, will have substantial impact in the therapy of microbial infections.